HRP20160506T1 - Neutralizirajuće prolaktin receptorsko protutijelo mat3 i njegova terapijska uporaba - Google Patents
Neutralizirajuće prolaktin receptorsko protutijelo mat3 i njegova terapijska uporaba Download PDFInfo
- Publication number
- HRP20160506T1 HRP20160506T1 HRP20160506TT HRP20160506T HRP20160506T1 HR P20160506 T1 HRP20160506 T1 HR P20160506T1 HR P20160506T T HRP20160506T T HR P20160506TT HR P20160506 T HRP20160506 T HR P20160506T HR P20160506 T1 HRP20160506 T1 HR P20160506T1
- Authority
- HR
- Croatia
- Prior art keywords
- antigen
- antibody
- host cell
- binding
- binding fragment
- Prior art date
Links
- 108010002519 Prolactin Receptors Proteins 0.000 title claims 5
- 102100029000 Prolactin receptor Human genes 0.000 title claims 5
- 101100495256 Caenorhabditis elegans mat-3 gene Proteins 0.000 title claims 3
- 230000003472 neutralizing effect Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 claims 21
- 102000036639 antigens Human genes 0.000 claims 21
- 108091007433 antigens Proteins 0.000 claims 21
- 239000012634 fragment Substances 0.000 claims 17
- 210000004027 cell Anatomy 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 150000007523 nucleic acids Chemical group 0.000 claims 5
- 241000282693 Cercopithecidae Species 0.000 claims 3
- 201000009273 Endometriosis Diseases 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 208000005641 Adenomyosis Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010006298 Breast pain Diseases 0.000 claims 2
- 241000282414 Homo sapiens Species 0.000 claims 2
- 101100409237 Homo sapiens PRLR gene Proteins 0.000 claims 2
- 208000006662 Mastodynia Diseases 0.000 claims 2
- 101100409239 Mus musculus Prlr gene Proteins 0.000 claims 2
- 229940046836 anti-estrogen Drugs 0.000 claims 2
- 230000001833 anti-estrogenic effect Effects 0.000 claims 2
- 208000011803 breast fibrocystic disease Diseases 0.000 claims 2
- 201000009274 endometriosis of uterus Diseases 0.000 claims 2
- 239000000328 estrogen antagonist Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 1
- 102000003946 Prolactin Human genes 0.000 claims 1
- 108010057464 Prolactin Proteins 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 210000000069 breast epithelial cell Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000006651 lactation Effects 0.000 claims 1
- 201000010260 leiomyoma Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000583 progesterone congener Substances 0.000 claims 1
- 229940097325 prolactin Drugs 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (22)
1. Protutijelo Mat3 ili njegovi fragmenti koji vežu antigen, koje antagonizira signalizaciju prolaktinom posredovanog receptora, naznačeno time da protutijelo ili njegovi fragmenti koji vežu antigen sadrže
a. promjenjivo teško područje sa sekvencom amino kiseline u skladu sa SEQ ID NO: 1, i
b. promjenjivo lako područje sa sekvencom amino kiseline u skladu sa SEQ ID NO: 2.
2. Protutijelo ili njegovi fragmenti koji vežu antigen prema zahtjevu 1, naznačeno time da protutijelo ili njegovi fragmenti koji vežu antigen sadrže regiju koja veže antigen koja se specifično veže na jednu ili više regija izvanstanične domene prolaktin receptora (PRLR) iz čovjeka, majmuna i miša, te pri čemu su sekvence amino kiseline za ljudski PRLR prikazane sa sekvencom amino kiseline od položaja 1 do 210 iz SEQ ID NO: 12 i ljudske polimorfne varijante iz SEQ ID NO: 12, sa sekvencom amino kiseline od položaja 1 do 210 majmunskog PRLR u skladu sa SEQ ID NO: 11 i mišjeg PRLR u skladu sa SEQ ID NO: 13.
3. Protutijelo ili njegovi fragmenti koji vežu antigen prema zahtjevu 2, naznačeno time da afinitet za izvanstaničnu domenu PRLR iz čovjeka, majmuna i miša je 100 nM, manje od 30 nM, ili s afinitetom od 10 nM, te pri čemu je afinitet izmjeren površinskom plazmonskom rezonancijom, na primjer sa Biacore.
4. Protutijelo ili njegovi fragmenti koji vežu antigen prema zahtjevu 1, naznačeno time da protutijelo sadrži regiju koja veže antigen koja se veže specifično na jednu ili više regija izvanstanične domene ljudske PRLR i pri čemu je afinitet 10 nM ili 1 nM, te pri čemu je afinitet izmjeren površinskom plazmonskom rezonancijom, na primjer sa Biacore.
5. Protutijelo ili njegovi fragmenti koji vežu antigen prema bilo kojem od zahtjeva 1 do 4 naznačeno time da konstantne domene teškog lanca su modificirani ili nemodificirani IgG1, IgG2, IgG3 ili IgG4.
6. Izolirana sekvenca nukleinske kiseline naznačena time da kodira protutijelo ili fragment koji veže antigen prema bilo kojem od zahtjeva 1 do 5.
7. Izolirana sekvenca nukleinske kiseline prema zahtjevu 6, naznačena time da su izolirane sekvence nukleinske kiseline u skladu sa SEQ ID NO: 3 i 4.
8. Ekspresijski vektor naznačen time da sadrži sekvencu nukleinske kiseline prema zahtjevu 6 ili 7.
9. Stanica domaćin koja sadrži vektor prema zahtjevu 8 ili molekulu nukleinske kiseline prema zahtjevu 6 ili 7, naznačena time da je stanica domaćin viša eukariotska stanica domaćin, niža eukariotska stanica domaćin, ili prokariotska stanica.
10. Stanica domaćin prema zahtjevu 9, naznačena time da viša eukariotska stanica domaćin je stanica sisavca.
11. Stanica domaćin prema zahtjevu 9, naznačena time da niža eukariotska stanica domaćin je stanica kvasca.
12. Stanica domaćin prema zahtjevu 9, naznačena time da prokariotska stanica je bakterijska stanica.
13. Postupak korištenja stanice domaćina prema bilo kojem od zahtjeva 9 do 12 za proizvodnju protutijela ili fragmenta koji veže antigen, naznačen time da sadrži kultiviranje stanice domaćina prema zahtjevu 9 pod pogodnim uvjetima i prikupljanje navedenih protutijela.
14. Protutijelo ili fragment koji veže antigen naznačeno time da se proizvodi postupkom prema zahtjevu 13.
15. Protutijelo ili fragment koji veže antigen prema bilo kojem od zahtjeva 1 do 5 naznačeno time da se pročišćava do najmanje 95% homogenosti po težini.
16. Protutijelo ili fragment koji veže antigen prema bilo kojem od zahtjeva 1 do 5 naznačeno time da je za uporabu kao lijek.
17. Farmaceutski pripravak naznačen time da sadrži protutijelo ili fragment koji veže antigen prema bilo kojem od zahtjeva 1 do 5 i farmaceutski prihvatljiv nosač koji sadrži ekscipijente i pomoćna sredstva.
18. Komplet koji sadrži protutijelo prema zahtjevu 1 do 5 naznačen time da sadrži terapeutski učinkovitu količinu protutijela Mat3, pakiranu u spremnik, navedeni komplet proizvoljno sadrži i drugo terapeutsko sredstvo, te nadalje sadrži oznaku pričvršćenu ili pakiranu sa spremnikom, oznaka opisuje sadržaj spremnika i pruža navode i/ili upute o korištenju sadržaja spremnika za liječenje endometrioze, adenomioze, benigne bolesti dojke i mastalgije, inhibiciju laktacije, hiper- i normo-prolaktinemijskog gubitka kose, benigne hiperplazije prostate, fibroida ili za primjenu za ne-hormonsku žensku kontracepciju ili za liječenje žena koje su pod kombiniranom hormonskom terapijom, estrogen plus progestin terapijom, za inhibiciju proliferacije stanica epitela dojke ili za liječenje i prevenciju raka dojke otpornog na terapiju antiestrogenom.
19. Protutijelo ili fragment koji veže antigen prema bilo kojem od zahtjeva 1 do 5 naznačeno time da je za uporabu u lijeku za liječenje i/ili prevenciju endometrioze i adenomioze, interne endometrioze.
20. Protutijelo ili fragment koji veže antigen prema bilo kojem od zahtjeva 1 do 5 naznačeno time da je za uporabu u lijeku za liječenje benigne bolesti dojke i mastalgije.
21. Protutijelo ili fragment koji veže antigen prema bilo kojem od zahtjeva 1 do 5 naznačeno time da je za uporabu u lijeku za liječenje ili prevenciju raka dojke otpornog na terapiju antiestrogenom.
22. Farmaceutski pripravak prema zahtjevu 17 naznačen time da sadrži PRLR protutijela ili fragment koji veže antigen prema bilo kojem od zahtjeva 1 do 5, u kombinaciji s najmanje jednim drugim sredstvom.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11168644A EP2530089A1 (en) | 2011-06-03 | 2011-06-03 | Neutralising prolactin receptor antibody Mat3 and its therapeutical use |
| EP12729030.2A EP2714740B1 (en) | 2011-06-03 | 2012-05-31 | Neutralizing prolactin receptor antibody mat3 and its therapeutic use |
| PCT/EP2012/060078 WO2012163932A1 (en) | 2011-06-03 | 2012-05-31 | Neutralizing prolactin receptor antibody mat3 and its therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160506T1 true HRP20160506T1 (hr) | 2016-06-17 |
Family
ID=46331236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160506TT HRP20160506T1 (hr) | 2011-06-03 | 2016-05-12 | Neutralizirajuće prolaktin receptorsko protutijelo mat3 i njegova terapijska uporaba |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US9353186B2 (hr) |
| EP (2) | EP2530089A1 (hr) |
| JP (1) | JP5859641B2 (hr) |
| KR (1) | KR101920521B1 (hr) |
| CN (1) | CN103764679B (hr) |
| AP (1) | AP2013007266A0 (hr) |
| AR (1) | AR086631A1 (hr) |
| AU (1) | AU2012264765B2 (hr) |
| BR (1) | BR112013030995B1 (hr) |
| CA (1) | CA2837736C (hr) |
| CL (1) | CL2013003459A1 (hr) |
| CO (1) | CO6852025A2 (hr) |
| CR (1) | CR20130632A (hr) |
| CU (1) | CU20130163A7 (hr) |
| CY (1) | CY1117660T1 (hr) |
| DK (1) | DK2714740T3 (hr) |
| DO (1) | DOP2013000285A (hr) |
| EA (1) | EA029316B1 (hr) |
| EC (1) | ECSP13013063A (hr) |
| ES (1) | ES2572215T3 (hr) |
| HK (1) | HK1195081A1 (hr) |
| HR (1) | HRP20160506T1 (hr) |
| HU (1) | HUE028775T2 (hr) |
| IL (1) | IL229504B (hr) |
| MA (1) | MA35237B1 (hr) |
| ME (1) | ME02659B (hr) |
| MX (1) | MX343683B (hr) |
| PE (1) | PE20141158A1 (hr) |
| PL (1) | PL2714740T3 (hr) |
| RS (1) | RS54727B1 (hr) |
| SG (1) | SG195060A1 (hr) |
| SI (1) | SI2714740T1 (hr) |
| TN (1) | TN2013000501A1 (hr) |
| TW (1) | TWI548649B (hr) |
| UY (1) | UY34116A (hr) |
| WO (1) | WO2012163932A1 (hr) |
| ZA (1) | ZA201309683B (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140135233A (ko) | 2012-03-14 | 2014-11-25 | 리제너론 파마슈티칼스 인코포레이티드 | 다중특이성 항원-결합 분자 및 그것의 용도 |
| LT2935331T (lt) | 2012-12-24 | 2018-06-25 | Abbvie Inc. | Prolaktino receptorių surišantys baltymai ir jų panaudojimas |
| TWI641620B (zh) * | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| MX2017017117A (es) | 2015-07-06 | 2018-03-06 | Regeneron Pharma | Moleculas multiespecificas de union a antigenos y usos de estas. |
| WO2017190079A1 (en) | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| EP3548514A1 (en) | 2016-11-29 | 2019-10-09 | Regeneron Pharmaceuticals, Inc. | Methods of treating prlr positive breast cancer |
| TW201836647A (zh) | 2017-04-06 | 2018-10-16 | 美商艾伯維有限公司 | 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途 |
| JP2020527552A (ja) | 2017-07-10 | 2020-09-10 | バイエル・ファルマ・アクティエンゲゼルシャフト | 男性型脱毛症および女性型脱毛症用のプロラクチン受容体抗体 |
| ES2973864T3 (es) * | 2017-08-10 | 2024-06-24 | Grifols Diagnostic Solutions Inc | Composiciones, métodos y/o kits que comprenden un dominio extracelular de CD38 recombinante humano |
| MX2020008274A (es) | 2018-02-07 | 2020-11-11 | Regeneron Pharma | Metodos y composiciones para la administracion de proteinas terapeuticas. |
| UY39610A (es) | 2021-01-20 | 2022-08-31 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| CN116655791B (zh) * | 2023-05-06 | 2023-11-07 | 浙江触奇生物科技有限公司 | 一种抗泌乳素受体的纳米抗体、重组载体、重组菌和应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| EP0571613B1 (en) | 1991-12-13 | 2003-09-17 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
| GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
| WO2003008583A2 (en) | 2001-03-02 | 2003-01-30 | Sagres Discovery | Novel compositions and methods for cancer |
| US7705120B2 (en) | 2001-06-21 | 2010-04-27 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| EP1325930A1 (en) * | 2002-01-08 | 2003-07-09 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Mammal prolactin variants |
| AU2006235258A1 (en) | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics Inc. | Cancer-related genes |
| US7422899B2 (en) | 2005-10-05 | 2008-09-09 | Biogen Idec Ma Inc. | Antibodies to the human prolactin receptor |
| CA2661023C (en) | 2006-08-18 | 2017-08-15 | Novartis Ag | Prlr-specific antibody and uses thereof |
| EP2332995A1 (en) * | 2009-12-10 | 2011-06-15 | Bayer Schering Pharma Aktiengesellschaft | Neutralizing prolactin receptor antibodies and their therapeutic use |
-
2011
- 2011-06-03 EP EP11168644A patent/EP2530089A1/en not_active Withdrawn
-
2012
- 2012-05-31 SI SI201230553A patent/SI2714740T1/sl unknown
- 2012-05-31 AU AU2012264765A patent/AU2012264765B2/en active Active
- 2012-05-31 EP EP12729030.2A patent/EP2714740B1/en active Active
- 2012-05-31 EA EA201301356A patent/EA029316B1/ru not_active IP Right Cessation
- 2012-05-31 AP AP2013007266A patent/AP2013007266A0/xx unknown
- 2012-05-31 BR BR112013030995-4A patent/BR112013030995B1/pt active IP Right Grant
- 2012-05-31 CA CA2837736A patent/CA2837736C/en active Active
- 2012-05-31 MX MX2013014174A patent/MX343683B/es active IP Right Grant
- 2012-05-31 CN CN201280038107.4A patent/CN103764679B/zh active Active
- 2012-05-31 DK DK12729030.2T patent/DK2714740T3/da active
- 2012-05-31 JP JP2014513160A patent/JP5859641B2/ja active Active
- 2012-05-31 KR KR1020137034848A patent/KR101920521B1/ko active IP Right Grant
- 2012-05-31 US US14/123,517 patent/US9353186B2/en active Active
- 2012-05-31 ES ES12729030T patent/ES2572215T3/es active Active
- 2012-05-31 HU HUE12729030A patent/HUE028775T2/en unknown
- 2012-05-31 PL PL12729030T patent/PL2714740T3/pl unknown
- 2012-05-31 SG SG2013085816A patent/SG195060A1/en unknown
- 2012-05-31 WO PCT/EP2012/060078 patent/WO2012163932A1/en active Application Filing
- 2012-05-31 RS RS20160322A patent/RS54727B1/sr unknown
- 2012-05-31 PE PE2013002749A patent/PE20141158A1/es active IP Right Grant
- 2012-05-31 ME MEP-2016-91A patent/ME02659B/me unknown
- 2012-06-01 TW TW101119849A patent/TWI548649B/zh active
- 2012-06-01 AR ARP120101933A patent/AR086631A1/es active Pending
- 2012-06-01 UY UY0001034116A patent/UY34116A/es not_active Application Discontinuation
-
2013
- 2013-11-19 IL IL229504A patent/IL229504B/en active IP Right Grant
- 2013-12-02 MA MA36513A patent/MA35237B1/fr unknown
- 2013-12-02 TN TNP2013000501A patent/TN2013000501A1/fr unknown
- 2013-12-03 DO DO2013000285A patent/DOP2013000285A/es unknown
- 2013-12-03 CR CR20130632A patent/CR20130632A/es unknown
- 2013-12-03 CU CU2013000163A patent/CU20130163A7/es unknown
- 2013-12-03 CO CO13283823A patent/CO6852025A2/es not_active Application Discontinuation
- 2013-12-03 EC ECSP13013063 patent/ECSP13013063A/es unknown
- 2013-12-03 CL CL2013003459A patent/CL2013003459A1/es unknown
- 2013-12-20 ZA ZA2013/09683A patent/ZA201309683B/en unknown
-
2014
- 2014-08-18 HK HK14108441.2A patent/HK1195081A1/zh unknown
-
2016
- 2016-04-28 US US15/140,629 patent/US9777063B2/en active Active
- 2016-05-12 HR HRP20160506TT patent/HRP20160506T1/hr unknown
- 2016-06-17 CY CY20161100549T patent/CY1117660T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160506T1 (hr) | Neutralizirajuće prolaktin receptorsko protutijelo mat3 i njegova terapijska uporaba | |
| HRP20170016T1 (hr) | Neutralizirajuća antitijela prolaktin receptora i njihova terapeutska uporaba | |
| ES2931223T3 (es) | Anticuerpo de un solo dominio para CTLA4 y proteína procedente del mismo | |
| US20200197497A1 (en) | Peptidic chimeric antigen receptor t cell switches and uses thereof | |
| AU2017345479B2 (en) | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof | |
| US10800828B2 (en) | Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer | |
| AU2011292197B2 (en) | Antibodies that bind myostatin, compositions and methods | |
| JP6831783B2 (ja) | 抗体薬物コンジュゲート | |
| HRP20200652T1 (hr) | Ljudska antitijela na fel d1 i metode njihove primjene | |
| HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
| CN113316590A (zh) | 抗nkg2a抗体及其用途 | |
| CN109475551A (zh) | 用于***的抗-egfr组合 | |
| CN109152832A (zh) | 用于***的抗-cd20组合 | |
| HRP20210736T1 (hr) | Protutijela anti-htra1 i načini njihove uporabe | |
| CN103282054A (zh) | 抗dig抗体和与肽缀合的地高辛配基的复合物的药物组合物 | |
| CN102170908A (zh) | 向个体的肿瘤引流***递送cd40激动剂 | |
| CN117736325A (zh) | 分离抗体及其应用 | |
| JP2017520572A (ja) | 抗ｈｓｖ抗体の外用適用 | |
| JP6475225B2 (ja) | 治療上の使用のための抗ｂａｇ３抗体 | |
| TW202132338A (zh) | 針對類-tnf配體1a (tl1a)之人類化抗體及其用途 | |
| EP3737700A1 (en) | Antibodies against tim3 and uses thereof | |
| US20220396623A1 (en) | Uses of anti-icos antibodies | |
| CN113748130A (zh) | Tsg-6抗体和其用途 | |
| TW202313683A (zh) | 抗nkg2a抗體及組合物 | |
| Chen et al. | Prevention of genital herpes in a guinea pig model using a glycoprotein D-specific single chain antibody as a microbicide |